-
Anacetrapib is a CETP
inhibitor which was
being developed to
treat elevated cholesterol levels in an
effort to
prevent cardiovascular disease. In 2017...
- Succeeded:
Anacetrapib. In 2017, the
REVEAL trial based on more than 30,000 parti****nts
showed a
modest benefit of the
addition of
anacetrapib to statin...
- as a
screening tool for
those most at risk: men over the age of 65.
Anacetrapib is a
cholesteryl ester transfer protein inhibitor that
raises high-density...
-
Ester Transfer Protein (CETP)
inhibitors include the
agents torcetrapib,
anacetrapib and obicetrapib. They
block transfer of
cholesterol from "good" HDL particles...
-
inhibitors (cholesteryl
ester transfer protein), 1
candidate is in trials. (
Anacetrapib) It is
expected that
these drugs will
mainly increase HDL
while lowering...
- Am | An–Ap | Aq–Ar | As–Az An-DTPA An-MAA An-sulfur
colloid Ana-Kit
anacetrapib (USAN, INN) Anacin-3 Anadrol-50
Anafranil anagestone (INN) anagliptin...
-
Merck conducted early-stage
clinical trials but
ultimately abandoned Anacetrapib. The
diabetes research is led by
CohBar Inc., a
biotech company that...
-
inhibitors were
previously under development. One was Merck's MK-0859
anacetrapib,
which in
initial studies did not
increase blood pressure. In 2017, its...
-
treatment of dyslipidemia,
though significant caution is warranted.
Anacetrapib is the
fourth CETP
inhibitor being tried for
cardiovascular benefit In...
-
chloroformate completes the
synthesis of
torcetrapib (8). CETP
inhibitor Anacetrapib, CETP
inhibitor undergoing development by
Merck Dalcetrapib, CETP inhibitor...
